Takara Holdings×Nxera Pharma
Different ways of making money, on the same scale.
Same yardstick
| Metric | Takara HoldingsFY ending Mar 2026 | Nxera PharmaFY ending Dec 2023 |
|---|---|---|
| Revenue | ¥394.3B | ¥12.8B |
| COGS ratio | 67.6% | — |
| Operating margin | 4.3% | — |
| Net margin | 3.0% | -56.3% |
| FCF margin | -1.2% | — |
Highlighted = best value for that metric
Compare industry percentiles by axis
Each row uses the same 0–100 scale. Dots show each company's rank within its primary industry.
- Takara HoldingsPrimary industry: Alcoholic Beverages
- Nxera PharmaPrimary industry: Biotech & Regenerative Medicine
CompanyRank
Revenue growth
- Takara Holdings64.37 peers
- Nxera PharmaN/A
- Takara Holdings
Profitability
- Takara Holdings7.17 peers
- Nxera PharmaN/A
- Takara Holdings
Cash conversion
- Takara Holdings507 peers
- Nxera PharmaN/A
- Takara Holdings
Efficiency
- Takara Holdings78.67 peers
- Nxera Pharma7.17 peers
- Takara Holdings
Financial strength
- Takara HoldingsN/A
- Nxera PharmaN/A
- Takara Holdings
Each dot is a company's percentile within its primary industry; peer groups may differ. Missing axes are labeled as unavailable. No combined score is calculated, and industry rank is not an investment recommendation.
Money flows side by side
Chart height is proportional to revenue.
Takara Holdings¥394.3B · keeps ¥4 per ¥100
Nxera Pharma¥12.8B
※ Cost of revenue is not disclosed; expenses are combined
※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains
Analyze this page with AI
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.